Fig. 1 · Structure

Documents & Downloads

Abemaciclib (LY2835219)

Cat. No. A12989 CAS 1231929-97-7

CDK4/6 inhibitor

abemaciclib (LY2835219) is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

In Stock

Publications for Abemaciclib

10 publications citing this product

  1. Che-Yuan Hsu, .et al. , Br J Cancer, 2024, Sep;131(5):944-953 PMID: 38987365
  2. Yukinori Ozaki, .et al. , Am J Cancer Res, 2023, Oct 15;13(10):4931-4943 PMID: 37970362
  3. Elaheh S Abutorabi, .et al. , Mol Biol Rep, 2023, May;50(5):4073-4082 PMID: 36877344
  4. Yoshinori Tanaka, .et al. , Biochem Biophys Res Commun, 2022, Jul 23;614:191-97 PMID: 35598430
  5. Sumire Suzuki, .et al. , Oncol Rep, 2022, Feb;47(2):40 PMID: 34958115
  6. Kana Nakatani, .et al. , Int J Hematol, 2020, Oct 17 PMID: 33068248
  7. Ryohei Ogata, .et al. , Breast Cancer, 2020, Aug 28 PMID: 32860163
  8. Elaheh Seyed Abutorabi, .et al. , Rep Biochem Mol Biol, 2020, Jan; 8(4): 438-445 PMID: 32582803
  9. Hidemasa Matsuo, .et al. , Blood Adv, 2018, Nov 13; 2(21): 2879-2889 PMID: 30381403
  10. Iriyama N, .et al. , Leuk Lymphoma, 2018, Jun;59(6):1439-1450 PMID: 28918692

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Abemaciclib (LY2835219) inhibits CDK4/cyclin D1 and CDK6/cyclin D1 and exhibits ATP-competitive kinetics. With the methanesulfonate salt, biochemical IC50 values were 2.0 ± 0.4 nmol/L (n = 5) and 9.9 nmol/L (n = 1), respectively. The same profile detected CDK9/cyclin T1 inhibition; selectivity is relative and assay-dependent. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Cdk4/cyclin D1 IC50 2 nM
CDK6/cyclinD1 IC50 10 nM
CDK9/cyclinT1 IC50 57 nM
CDK5/p35 IC50 287 nM
Cdk5/p25 IC50 355 nM
CDK2/cyclinE IC50 504 nM
CDK1/cyclinB1 IC50 1627 nM
CDK7/Mat1/cyclinH1 IC50 3910 nM
PIM1 IC50 50 nM
PIM2 IC50 3400 nM
HIPK2 IC50 31 nM
DYRK2 IC50 61 nM
CK2 IC50 117 nM
GSK3b IC50 192 nM
JNK3 IC50 389 nM
FLT3 (D835Y) IC50 403 nM
DRAK1 IC50 659 nM
FLT3 IC50 3960 nM

18 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A 172 EC50 0.2 μM Antiproliferative activity against human A172 assessed as reduction in cell viability incubated for 5 days by CyQuantGR dye-based fluorescence assay [PMID: 31307887]
A549 IC50 253 nM Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 4 to 6 days by cell titer-glo luminescent cell viability assay [PMID: 31200237]
COLO 205 IC50 0.217 μM Antiproliferative activity against human COLO205 cells after 96 hrs by CCK8 assay [PMID: 29459274]
COLO 205 IC50 0.46 μM Antiproliferative activity against human COLO205 cells after 96 hrs by CCK-8 assay [PMID: 29074254]
COLO 205 IC50 120 nM Inhibition of CDK4/6 in human COLO205 cells assessed as inhibition of Rb phosphorylation after 24 hrs by propidium iodide staining-based laser-scanning fluorescence microplate cytometric analysis [PMID: 26115571]
COLO 205 IC50 253 nM Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth incubated for 4 to 6 days by cell titer-glo luminescent cell viability assay [PMID: 31200237]
COLO 205 IC50 253 nM Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition measured after 4 to 6 days by celltiter-glo luminescent cell viability assay [PMID: 32200202]
CWR22R GI50 0.348 μM Antiproliferative activity against human 22Rv1 cells assessed as growth inhibition measured after 72 hrs by CCK8 assay [PMID: 34875521]
DBTRG-05MG EC50 0.19 μM Antiproliferative activity against human DBTRG-05MG assessed as reduction in cell viability incubated for 5 days by CyQuantGR dye-based fluorescence assay [PMID: 31307887]
EMT6 IC50 4.18 μM Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 35447031]
HEK293 GI50 10.925 μM Antiproliferative activity against human HEK293 cells assessed as growth inhibition measured after 72 hrs by CCK8 assay [PMID: 34875521]
HeLa IC50 768 nM Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay [PMID: 31382120]
HL-60 GI50 0.664 μM Antiproliferative activity against human HL-60 cells assessed as growth inhibition measured after 72 hrs by CCK8 assay [PMID: 34875521]
HT-22 IC50 12.2 μM Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay [PMID: 36876904]
HUVEC IC50 403 nM Antiproliferative activity against HUVEC cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay [PMID: 31382120]
Jurkat GI50 4.63 μM Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK8 assay [PMID: 32129996]
K562 GI50 0.624 μM Antiproliferative activity against human K562 cells assessed as growth inhibition measured after 72 hrs by CCK8 assay [PMID: 34875521]
M059J EC50 9.24 μM Antiproliferative activity against human M059J assessed as reduction in cell viability incubated for 5 days by CyQuantGR dye-based fluorescence assay [PMID: 31307887]
MCF-10A GI50 5.088 μM Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay [PMID: 36350721]

19 records · Scroll to view more

Abemaciclib (LY2835219) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Abemaciclib (LY2835219) from 2 published references. In vitro models include Colo-205 human colorectal cancer cells. In vivo models include H460 lung carcinoma xenografts in female CD1 nu/nu mice.

Abemaciclib (LY2835219) In Vitro Studies

In Colo-205 cells, 24-hour LY2835219 exposure inhibited Rb Ser780 phosphorylation and increased the G1 population, with IC50 120 ± 36 nmol/L (n = 6) and G1 EC50 72 ± 31 nmol/L (n = 7), respectively (geometric means ± SD). These are cellular assay endpoints for the methanesulfonate salt. [1]

Cell-cycle effects depend on model and concentration. A later study observed G2 accumulation with abemaciclib at higher concentrations in MCF7 cells and in pRb-deficient PDX12-58 cells; palbociclib and ribociclib did not alter the cell-cycle distribution in the pRb-deficient model. The cellular response therefore extends beyond a universal Rb-dependent G1 arrest. [2]

CDK4/6 biochemical inhibition and selectivity limits

Biochemical assay · Human kinase/cyclin complexes; CDK4/cyclin D1 and CDK6/cyclin D1 use a C-terminal Rb fragment substrate [1]

LY2835219 inhibited CDK4/6 in a radiometric assay and showed ATP-competitive kinetics. CDK9 inhibition in the same profile limits any claim of absolute CDK4/6 specificity. IC50 and Ki are assay endpoints, not treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CDK4/cyclin D1 inhibitionIC50 2.0 ± 0.4 nmol/L (n = 5)[1]
CDK6/cyclin D1 inhibitionIC50 9.9 nmol/L (n = 1)[1]
CDK4/cyclin D1 inhibitionKi[ATP] 0.6 ± 0.3 nmol/L (n = 2)[1]
CDK6/cyclin D1 inhibitionKi[ATP] 2.4 ± 1.2 nmol/L (n = 2)[1]
CDK9/cyclin T1 inhibitionIC50 57 ± 42 nmol/L (n = 4)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10-point, 1:3 serial dilution; reported starting compound concentration 20 μM
Exposure duration
90 min for CDK4/6 inhibition assays (ESM1 methods)
Method
Radiometric-filter binding; four-parameter IC50 fit; competitive Michaelis–Menten kinetic analysis
Vehicle
Compound dilution buffer 20% DMSO; DMSO-only and EDTA background controls described. This is not asserted as the final reaction DMSO fraction.
Reported limits
No cross-paper comparison of assay ATP conditions is made.
Methods and source locations

Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: LY2835219

Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.

Table 1 biochemical rows and footnotes a–b; Enzymatic profiling; Results, Identification of LY2835219

CDK4/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling

CDK6/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling

CDK4/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling

CDK6/cyclin D1 inhibition: Radiometric Rb-fragment assay for CDK4/6; ATP-varied competitive kinetic fitting for Ki. For n > 1, mean of independent determinations ± SD. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling

CDK9/cyclin T1 inhibition: Biochemical kinase profiling, Table 1. CDK9-specific assay protocol was not recovered from the inspected main text; it is not assigned the CDK4/6 Rb-fragment method. — Table 1 biochemical profiling, footnotes a–b; Materials and methods, Enzymatic profiling

Rb phosphorylation and G1 accumulation in Colo-205 cells

Cell-based study · Colo-205 human colorectal cancer cells [1]

A 24-hour multiplexed assay linked reduced Rb Ser780 phosphorylation to increased 2N DNA content and reduced cell-number expansion. Table 1 reports geometric-mean cellular potency estimates ± SD, with different n for the two endpoints.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rb Ser780 phosphorylation inhibitionIC50 120 ± 36 nmol/L (n = 6; geometric mean ± SD)[1]
Accumulation of cells with 2N DNA content (G1)EC50 72 ± 31 nmol/L (n = 7; geometric mean ± SD)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10-point 1:3 series across 20 μM to 0.001 μM (ESM1 assay method)
Exposure duration
24 h
Method
Acumen Explorer multiplexed phospho-Rb immunofluorescence and propidium-iodide DNA-content analysis; four-parameter fits
Vehicle
0.25% final DMSO (ESM1)
Reported limits
The tested concentration series is a method range; it is not an IC50. No apoptosis measurement is inferred from reduced cell number.
Methods and source locations

Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: LY2835219

Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.

Figure 2a; Table 1 cellular rows and footnote d; Cell assays; ESM1, Cellular assay for inhibition of Phosphorylation of Retinoblastoma Protein and DNA Content Assay

Rb Ser780 phosphorylation inhibition: Multiplexed cellular imaging — Table 1 cellular profiling, footnote d; Figure 2a

Accumulation of cells with 2N DNA content (G1): Multiplexed cellular imaging — Table 1 cellular profiling, footnote d; Figure 2a

Concentration-dependent G1 and G2 cell-cycle responses

Cell-based study · MCF7 breast cancer cells at 24 and 48 h; pRb-deficient PDX12-58 (caption: PDX-1258) cells at 48 h [2]

In Figure 5, abemaciclib caused G1 arrest with reduced phospho-pRb in MCF7 cells and G2 accumulation at higher concentrations. In pRb-deficient PDX12-58 cells it caused G2 accumulation, whereas palbociclib and ribociclib did not alter the cell-cycle distribution. These observations constrain a universal, exclusively Rb-dependent G1-arrest mechanism; this experiment alone does not establish the responsible secondary kinase.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-cycle distribution and phospho-pRb stainingQualitative cell-cycle response Higher-concentration G2 accumulation; one representative replicate out of three shown[2]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 5: 0, 0.1, 0.3, 1.0 and 3.2 μM; matched inhibitor comparison
Exposure duration
MCF7: 24 or 48 h; PDX12-58: 48 h
Method
Hoechst nuclear DNA-content imaging and phospho-pRb Ser807/811 immunofluorescence; representative of three replicates
Vehicle
Zero-drug controls shown; DMSO controls described in shared dose-response methods
Reported limits
Final DMSO fraction not specified in the inspected Figure 5 methods. No exact cell-cycle percentages read from histograms; 0.3 μM is a response-context threshold in Results, not an IC50.
Methods and source locations

Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: Abemaciclib

Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.

Figure 5 image/caption; Results, Abemaciclib blocks cells in the G2 phase of the cell cycle; STAR Methods, Phospho-pRb immunofluorescence and cell cycle analysis; Key Resources Table

Cell-cycle distribution and phospho-pRb staining: Hoechst DNA content and phospho-pRb Ser807/811 imaging — Figure 5 and caption; Results, Abemaciclib blocks cells in the G2 phase of the cell cycle

Abemaciclib (LY2835219) In Vivo Studies

In H460 lung cancer xenografts, oral LY2835219 methanesulfonate once daily for 21 days gave percent delta T/C values of 84 (25 mg/kg; NS), 60 (50 mg/kg; P <0.001), and 36 (100 mg/kg; P <0.001) on day 35. Lower values indicate less tumor growth relative to control under the paper’s metric; these values are not percentages of tumor-growth inhibition. [1]

H460 xenograft response includes a nonsignificant low-dose result

Animal study · H460 lung carcinoma xenografts in female CD1 nu/nu mice [1]

The H460 experiment showed a dose-associated reduction in percent delta T/C at 50 and 100 mg/kg, but the 25 mg/kg group was not significant. The table also lists PD0332991 at 50 mg/kg: percent delta T/C 60, P <0.001. This is model-specific tumor-growth evidence for the methanesulfonate salt, not a survival or human-efficacy result.

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
21 days; Table 2 outcome calculated on day 35
Vehicle
1% hydroxyethyl cellulose + 0.1% antifoam in 25 mM phosphate buffer, pH 2
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY2835219 25 mg/kgVehicle-treated tumor-bearing micePercent delta T/C = 84 on day 35; P NS versus control. Table defines 100% as treated volume equal to control, 0% as equal to baseline, and −100% as zero volume, with linear interpolation.[1]
LY2835219 50 mg/kgVehicle-treated tumor-bearing micePercent delta T/C = 60 on day 35; P <0.001 versus control. Table defines 100% as treated volume equal to control, 0% as equal to baseline, and −100% as zero volume, with linear interpolation.[1]
LY2835219 100 mg/kgVehicle-treated tumor-bearing micePercent delta T/C = 36 on day 35; P <0.001 versus control. Table defines 100% as treated volume equal to control, 0% as equal to baseline, and −100% as zero volume, with linear interpolation.[1]
LY2835219 25 mg/kg
Model: H460 human lung cancer subcutaneous xenografts in female CD1 nu/nu mice, 5–6 weeks old at implantation
Reported limits: H460 group size and uncertainty for this tabulated endpoint are not specified in the inspected main text/table. NS is retained as reported; no exact P value inferred.
LY2835219 50 mg/kg
Model: H460 human lung cancer subcutaneous xenografts in female CD1 nu/nu mice, 5–6 weeks old at implantation
Reported limits: H460 group size and uncertainty for this tabulated endpoint are not specified in the inspected main text/table. NS is retained as reported; no exact P value inferred.
LY2835219 100 mg/kg
Model: H460 human lung cancer subcutaneous xenografts in female CD1 nu/nu mice, 5–6 weeks old at implantation
Reported limits: H460 group size and uncertainty for this tabulated endpoint are not specified in the inspected main text/table. NS is retained as reported; no exact P value inferred.
Methods and source locations

Compound reported in the paper: abemaciclib (LY2835219); Compound label in the paper: LY2835219

Reported compound-level evidence; tested material and formulation apply only to this paper. No salt conversion or SKU/lot equivalence is inferred.

Table 2, H460 lung rows and metric definition; Materials and methods, Tumor xenograft studies

LY2835219 25 mg/kg · Table 2, H460 lung rows and metric footnote; Materials and methods, Tumor xenograft studies

LY2835219 50 mg/kg · Table 2, H460 lung rows and metric footnote; Materials and methods, Tumor xenograft studies

LY2835219 100 mg/kg · Table 2, H460 lung rows and metric footnote; Materials and methods, Tumor xenograft studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1231929-97-7
Applications CDK4/6 inhibitor
Formula C27H32F2N8
Molecular Weight 506.59
Synonyms LY 2835219
SMILES
CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 6 mg/mL (11.84 mM)
Water Insoluble
Ethanol 8 mg/mL (15.79 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Abemaciclib (LY2835219) Research References

  1. [1] Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational new drugs (2014). PMID: 24919854 DOI: 10.1007/s10637-014-0120-7 Source material
  2. [2] Hafner M, Mills CE, Subramanian K, et al. Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell chemical biology (2019). PMID: 31178407 DOI: 10.1016/j.chembiol.2019.05.005 Source material

Publications

10 publications citing this product

  1. Che-Yuan Hsu, .et al. , Br J Cancer, 2024, Sep;131(5):944-953 PMID: 38987365
  2. Yukinori Ozaki, .et al. , Am J Cancer Res, 2023, Oct 15;13(10):4931-4943 PMID: 37970362
  3. Elaheh S Abutorabi, .et al. , Mol Biol Rep, 2023, May;50(5):4073-4082 PMID: 36877344
  4. Yoshinori Tanaka, .et al. , Biochem Biophys Res Commun, 2022, Jul 23;614:191-97 PMID: 35598430
  5. Sumire Suzuki, .et al. , Oncol Rep, 2022, Feb;47(2):40 PMID: 34958115
  6. Kana Nakatani, .et al. , Int J Hematol, 2020, Oct 17 PMID: 33068248
  7. Ryohei Ogata, .et al. , Breast Cancer, 2020, Aug 28 PMID: 32860163
  8. Elaheh Seyed Abutorabi, .et al. , Rep Biochem Mol Biol, 2020, Jan; 8(4): 438-445 PMID: 32582803
  9. Hidemasa Matsuo, .et al. , Blood Adv, 2018, Nov 13; 2(21): 2879-2889 PMID: 30381403
  10. Iriyama N, .et al. , Leuk Lymphoma, 2018, Jun;59(6):1439-1450 PMID: 28918692

Added to your cart

View Cart Checkout
Loading...